2023年2月13日

印尼的Asa任超额认购8.15美元共同上调最高收获首都Kejora资本,马西Venture Partners 2月13日,2023年任Asa,这位DNA数据公司在印尼,已经在上周宣布关闭一个新的早期一轮815万美元的资金。这一轮超额认购由高层共同收获资本(美国硅谷),Kejora资本(Kejora-SBI轨道基金和资本马来西亚轨道),和玛西Venture Partners(美国硅谷),北极星的参与企业,Naya资本,PT诊断公司Utama Tbk,和许多知名的天使投资人,Asa任正非在一份声明中说。作为圆的一部分,Kejora资本的创始人和合伙人安迪Zain将加入公司董事会和首席执行官InterBIO Irawan无毒。这个资金,Asa任旨在使印尼的创新医疗行业通过纵向和基因组数据的使用加速药物发现和个性化的治疗。目前,该公司提供了一个直接面向消费者DNA测试,提供了360多份报告,包括倾向的健康风险,血统,和其他报告对于成年人来说,年轻的父母和孩子。在更大程度上,新注资将允许该公司扩大其努力深化其数字功能,临床生物信息学发展电子健康护照,clinico-genomic数据库集中在非传染性疾病。此外,该公司还计划增加医疗诊断和完成客户的健康数据。“我们公司非常满意这个资金。尤其值得信任的有信誉的合作伙伴和全球投资者对我们来说是一种荣誉。这也标志着一个里程碑式的成就在印尼的动态基因组和医疗行业发展。 Asa Ren is focused on building this industry with all our key partners,” said Founder and Chief Executive Officer of Asa Ren Aloysius Liang. Asa Ren is one of Indonesia’s first DNA data company which aims to accelerate drug discovery and personalized treatments for Southeast Asia’s healthcare industry by developing clinico-genomic databases from both healthy, and confirmed diagnostic populations. The firm’s suite of technology allows its customers to understand and manage their own healthcare data through their genetic profile, 360 phenotypes, and medical records for a more personalized healthcare experience. With the data model built, the platform powers Asa Ren’s data and innovation group to be an integral part of the pharmaceutical industry’s research, development and innovation arm, focused in human genetics across a spectrum of disease areas – including oncology, cardiovascular diseases, and in addition to other non-communicable diseases – in bringing a higher quality healthcare options. Asa Ren’s vision is to build the most diverse global clinico-genomic databases. “The Asa Ren team is uniquely positioned to bring genomics at scale to the Indonesian population. Their partnerships, their laboratory capabilities, and the scope of their ambition stood out for us,” said Adam Ghobarah from Top Harvest Capital. As one of the Board of Directors at Asa Ren, Andy Zain, the Founder and Managing Partner of Kejora Capital also shared his support for the biotechnology company succession. “Indonesia has the highest biodiversity in Southeast Asia with 1,300+ ethnic groups in the country. This provides a ripe opportunity for innovation and genetic research to improve the health and welfare of the country. We believe Asa Ren has all the right ingredients to capture this opportunity,” he said. According to the statement, Asa Ren has signed service agreements with more than 47 prominent hospital and clinic partners and is expecting to grow its distribution footprint to more than 60 hospital and clinic partners by the end of 2023. The company is looking forward to bringing its value-added capability to escalate and improve Indonesia’s healthcare and ecosystem.